PCN38 - NIVOLUMAB IS PREDICTED TO HAVE IMPROVED CLINICAL OUTCOMES OVER BEST SUPPORTIVE CARE IN A WESTERN POPULATION OF PRE-TREATED GASTRIC CANCER PATIENTS; AN INDIRECT TREATMENT COMPARISON ANALYSIS
Abstract
Authors
R. Young B.L. Jones M.P. Tan T. Ward P. McEwan C. Kiff A. Amadi J. Gordon